Index Ventures to unveil $578M European VC fund

Index Ventures is set to announce a new, $578 million European venture fund that will back a fresh slate of bets in the biotech field. And it's hired some top hands to run the fund: Dominique Vidal, the former CEO of Yahoo Europe, and Guido Magni, former global head of medical science at Roche. They plan to make about 15 investments averaging €25 million each, targeting companies with a revenue growth rate of 25 percent or more.

"We can provide pre-initial public offering financing, or funding for acquisitions to help companies achieve further growth," said Vidal, striking a tone that seemed to be geared more to technology than biotechnology.

- see this release
- read the report from the Financial Times

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.